The trend in oncological therapy is moving towards the targeted, risk-adapted and interdisciplinary treatment of tumors. INTRABEAM®, the innovative radiotherapy system from Carl Zeiss is an ideal platform to fulfill these requirements. It provides:
2Liu, Q., Schneider, F., Ma, L., Wenz, F., & Herskind, C. (2013). Relative Biologic Effectiveness (RBE) of 50 kV X-rays Measured in a Phantom for Intraoperative Tumor-Bed Irradiation. International Journal of Radiation Oncology*Biology*Physics, 85(4), 1127-1133.
INTRABEAM has been studied for more than 13 years and over 8,000 patients have received treatment for early breast cancer. It has been exclusively used to develop the targeted intraoperative radiotherapy technique implemented in the TARGIT-A Trial - a highly reputable international consortium that studies the efficacy of IORT in the treatment of early breast cancer versus traditional external beam radiotherapy (EBRT).
Targeted IORT with INTRABEAM is a risk-adapted individualized therapy that delivers low-energy X-rays directly into the tumor bed at the time of surgery (after tumor excision). During this procedure, the radiation is applied using a spherical applicator in a way that ensures direct contact with the target tissue. Radiation is delivered precisely to the area with the highest risk of tumor recurrence while minimizing radiation to healthy tissue.
For many cancer patients who develop spinal metastases in the natural course of their disease, percutaneous kyphoplasty and vertebroplasty are valuable treatment options. By using intraoperative radiotherapy with INTRABEAM during kyphoplasty or vertrebroplasty, the metastasis can be sterilized and if necessary vertebra simultaneously stabilized, a solution that results in reduction of patient’s discomfort. It also restores mobility, significantly enhancing the patient’s quality of life. The first clinical trial experience of this approach has yielded very promising results.3